Quince Therapeutics Inc. (QNCX)
1.21
0.08 (7.56%)
At close: Apr 25, 2025, 3:59 PM
1.25
3.19%
After-hours: Apr 25, 2025, 04:23 PM EDT
7.56% (1D)
| Bid | 1.14 |
| Market Cap | 53.35M |
| Revenue (ttm) | 168K |
| Net Income (ttm) | -56.83M |
| EPS (ttm) | -1.31 |
| PE Ratio (ttm) | -0.92 |
| Forward PE | -2.51 |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 41,665 |
| Avg. Volume (20D) | 120,608 |
| Open | 1.13 |
| Previous Close | 1.13 |
| Day's Range | 1.16 - 1.24 |
| 52-Week Range | 0.51 - 2.45 |
| Beta | 0.74 |
About QNCX
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The compan...
Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 36
Stock Exchange NASDAQ
Ticker Symbol QNCX
Website https://www.quincetx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for QNCX stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 685.12% from the latest price.
Stock Forecasts5 months ago
+19.5%
Quince Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
5 months ago
+19%
Quince Therapeutics shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced an $11 price target.
